Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.
The partners will test samples from an NSABP biobank on Nanostring's platform and with standard IHC to look for newer biomarkers of cancer immune evasion.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Grade 3 breast tumors generally have worse prognoses, but SEER data showed that Oncotype DX can identify a large proportion of patients who do well without chemo.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.